Moderna (MRNA) Leads August with 156% Gain Amid Market Recovery
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowIn August, several S&P 500 stocks rebounded sharply after facing months of bearish pressures. Moderna (MRNA) saw the highest gain, rising 156% due to promising results for its melanoma vaccine. Other significant winners included Palantir (PLTR) with a 51.45% increase and Veeva Systems (VEEV) at 40.2%. This market recovery is crucial as it highlights the resilience and potential growth in key sectors like biotechnology and enterprise software amid prior investor skepticism.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Moderna Inc. (MRNA)
Moderna is a biotech pioneering mRNA vaccines and therapeutics.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRNA news
- Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
- Moderna (MRNA) FDA Approval of Updated COVID-19 Vaccines Confirmed
- Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
- Moderna (MRNA) cancer vaccine shows positive breakthrough results
- Moderna (MRNA) mRNA Shot May Change Skin Cancer Treatment Landscape
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
